Biondo Investment Advisors LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,610 shares of the life sciences company’s stock after selling 1,588 shares during the quarter. Illumina comprises approximately 2.4% of Biondo Investment Advisors LLC’s holdings, making the stock its 11th largest position. Biondo Investment Advisors LLC’s holdings in Illumina were worth $8,687,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. KCG Holdings Inc. acquired a new stake in shares of Illumina in the first quarter valued at $290,000. Tudor Investment Corp ET AL acquired a new stake in shares of Illumina in the first quarter valued at $289,000. NN Investment Partners Holdings N.V. raised its position in shares of Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Illumina during the second quarter worth $345,000. Finally, LS Investment Advisors LLC raised its position in shares of Illumina by 3.5% during the second quarter. LS Investment Advisors LLC now owns 3,358 shares of the life sciences company’s stock worth $583,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 90.76% of the company’s stock.
Illumina, Inc. (ILMN) traded up $2.24 on Monday, hitting $211.27. The stock had a trading volume of 170,897 shares, compared to its average volume of 959,780. The company has a market cap of $30,516.92, a P/E ratio of 61.12, a PEG ratio of 3.45 and a beta of 0.74. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm’s revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.97 EPS. research analysts predict that Illumina, Inc. will post 3.75 EPS for the current year.
In related news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the sale, the senior vice president now owns 24,908 shares in the company, valued at approximately $5,263,807.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 172,446 shares of company stock valued at $35,486,114. 0.89% of the stock is currently owned by corporate insiders.
A number of equities research analysts have recently issued reports on the company. Argus boosted their target price on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 target price (up from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $184.00 to $228.00 in a research report on Wednesday, October 25th. Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up from $200.00) on shares of Illumina in a research report on Wednesday, October 25th. Finally, Bank of America Corporation boosted their target price on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.